[Docetaxel and prostate cancer: Early but not too early]

Bull Cancer. 2015 Sep;102(9):710-2. doi: 10.1016/j.bulcan.2015.06.006. Epub 2015 Jul 30.

[Article in French]

Authors

Nicolas Penel¹, Thomas Ryckewaert², Eric Yaovi Amela²

Affiliations

¹ Centre Oscar-Lambret, département de cancérologie générale, 3, rue Combemale, 59020 Lille cedex, France. Electronic address: [email protected].
² Centre Oscar-Lambret, département de cancérologie générale, 3, rue Combemale, 59020 Lille cedex, France.

PMID: 26235414
DOI: 10.1016/j.bulcan.2015.06.006

No abstract available

Publication types

News

MeSH terms

Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Congresses as Topic
Docetaxel
Humans
Life Expectancy
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / mortality
Prostatic Neoplasms, Castration-Resistant / pathology
Taxoids / therapeutic use*
Time Factors

Substances

Antineoplastic Agents
Taxoids
Docetaxel